# Telos Corp: financial statements, quarterly

TLS · Nasdaq · CIK 320121 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tls.md) · [Financials](/companies/tls/financials.md) · [Filings](/companies/tls/filings.md) · [Insiders](/companies/tls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tls/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [36.2](/filings/0000320121-24-000093.md) | [41.1 d](/filings/0000320121-25-000011.md) | [29.6](/filings/0000320121-25-000025.md) | [28.5](/filings/0000320121-25-000039.md) | [23.8](/filings/0000320121-25-000051.md) | [26.4 d](/filings/0000320121-26-000010.md) | [30.6](/filings/0000320121-26-000024.md) | [36.0](/filings/0000320121-26-000037.md) | [51.4](/filings/0000320121-25-000051.md) | [46.8 d](/filings/0000320121-26-000010.md) | [47.7](/filings/0000320121-26-000024.md) | [47.7](/filings/0000320121-26-000037.md) |
| Cost of revenue | $m | [23.2](/filings/0000320121-24-000093.md) | [27.0 d](/filings/0000320121-25-000011.md) | [18.7](/filings/0000320121-25-000025.md) | [18.8](/filings/0000320121-25-000039.md) | [20.6](/filings/0000320121-25-000051.md) | [15.8 d](/filings/0000320121-26-000010.md) | [18.4](/filings/0000320121-26-000024.md) | [24.0](/filings/0000320121-26-000037.md) | [30.9](/filings/0000320121-25-000051.md) | [30.4 d](/filings/0000320121-26-000010.md) | [30.4](/filings/0000320121-26-000024.md) | [31.1](/filings/0000320121-26-000037.md) |
| Gross profit | $m | [13.0](/filings/0000320121-24-000093.md) | [14.1 d](/filings/0000320121-25-000011.md) | [11.0](/filings/0000320121-25-000025.md) | [9.7](/filings/0000320121-25-000039.md) | [3.1](/filings/0000320121-25-000051.md) | [10.6 d](/filings/0000320121-26-000010.md) | [12.2](/filings/0000320121-26-000024.md) | [11.9](/filings/0000320121-26-000037.md) | [20.5](/filings/0000320121-25-000051.md) | [16.4 d](/filings/0000320121-26-000010.md) | [17.4](/filings/0000320121-26-000024.md) | [16.7](/filings/0000320121-26-000037.md) |
| Research and development | $m | [2.8](/filings/0000320121-24-000093.md) | [3.5 d](/filings/0000320121-25-000011.md) | [3.2](/filings/0000320121-25-000025.md) | [1.5](/filings/0000320121-25-000039.md) | [2.4](/filings/0000320121-25-000051.md) | [1.4 d](/filings/0000320121-26-000010.md) | [1.6](/filings/0000320121-26-000024.md) | [1.5](/filings/0000320121-26-000037.md) | [1.9](/filings/0000320121-25-000051.md) | [2.1 d](/filings/0000320121-26-000010.md) | [1.4](/filings/0000320121-26-000024.md) | [1.3](/filings/0000320121-26-000037.md) |
| Selling, general and administrative | $m | [22.7](/filings/0000320121-23-000054.md) | [10.0 d](/filings/0000320121-25-000011.md) | [16.2](/filings/0000320121-25-000025.md) | [16.9](/filings/0000320121-25-000039.md) | [23.2](/filings/0000320121-25-000051.md) | [19.1 d](/filings/0000320121-26-000010.md) | [19.6](/filings/0000320121-26-000024.md) | [20.3](/filings/0000320121-26-000037.md) | [21.1](/filings/0000320121-25-000051.md) | [17.9 d](/filings/0000320121-26-000010.md) | [14.6](/filings/0000320121-26-000024.md) | [15.0](/filings/0000320121-26-000037.md) |
| Operating income | $m | [(9.7)](/filings/0000320121-24-000093.md) | [(8.2) d](/filings/0000320121-25-000011.md) | [(8.4)](/filings/0000320121-25-000025.md) | [(8.6)](/filings/0000320121-25-000039.md) | [(28.9)](/filings/0000320121-25-000051.md) | [(9.9) d](/filings/0000320121-26-000010.md) | [(9.0)](/filings/0000320121-26-000024.md) | [(9.9)](/filings/0000320121-26-000037.md) | [(2.5)](/filings/0000320121-25-000051.md) | [(18.5) d](/filings/0000320121-26-000010.md) | [1.5](/filings/0000320121-26-000024.md) | [0.3](/filings/0000320121-26-000037.md) |
| Interest expense | $m | [0.2](/filings/0000320121-23-000054.md) | [0.2 d](/filings/0000320121-24-000017.md) | [0.2](/filings/0000320121-24-000020.md) | [0.2](/filings/0000320121-25-000039.md) | [0.2](/filings/0000320121-25-000051.md) | [0.2 d](/filings/0000320121-26-000010.md) | [0.1](/filings/0000320121-26-000024.md) | [0.1](/filings/0000320121-26-000037.md) | [0.1](/filings/0000320121-25-000051.md) | [0.1 d](/filings/0000320121-26-000010.md) | [0.1](/filings/0000320121-26-000024.md) | [0.1](/filings/0000320121-26-000037.md) |
| Income tax | $m | [0.0](/filings/0000320121-24-000093.md) | [(0.0) d](/filings/0000320121-25-000011.md) | [0.0](/filings/0000320121-25-000025.md) | [0.0](/filings/0000320121-25-000039.md) | [0.0](/filings/0000320121-25-000051.md) | [(0.0) d](/filings/0000320121-26-000010.md) | [(0.0)](/filings/0000320121-26-000024.md) | [0.0](/filings/0000320121-26-000037.md) | [0.0](/filings/0000320121-25-000051.md) | [(0.7) d](/filings/0000320121-26-000010.md) | [0.0](/filings/0000320121-26-000024.md) | [0.0](/filings/0000320121-26-000037.md) |
| Net income | $m | [(8.7)](/filings/0000320121-24-000093.md) | [(7.0) d](/filings/0000320121-25-000011.md) | [(7.4)](/filings/0000320121-25-000025.md) | [(7.8)](/filings/0000320121-25-000039.md) | [(28.1)](/filings/0000320121-25-000051.md) | [(9.3) d](/filings/0000320121-26-000010.md) | [(8.6)](/filings/0000320121-26-000024.md) | [(9.5)](/filings/0000320121-26-000037.md) | [(2.1)](/filings/0000320121-25-000051.md) | [(16.3) d](/filings/0000320121-26-000010.md) | [2.0](/filings/0000320121-26-000024.md) | [0.7](/filings/0000320121-26-000037.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0000320121-24-000093.md) | not reported | [(0.10)](/filings/0000320121-25-000025.md) | [(0.11)](/filings/0000320121-25-000039.md) | [(0.39)](/filings/0000320121-25-000051.md) | not reported | [(0.12)](/filings/0000320121-26-000024.md) | [(0.13)](/filings/0000320121-26-000037.md) | [(0.03)](/filings/0000320121-25-000051.md) | not reported | [0.03](/filings/0000320121-26-000024.md) | [0.01](/filings/0000320121-26-000037.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0000320121-24-000093.md) | not reported | [(0.10)](/filings/0000320121-25-000025.md) | [(0.11)](/filings/0000320121-25-000039.md) | [(0.39)](/filings/0000320121-25-000051.md) | not reported | [(0.12)](/filings/0000320121-26-000024.md) | [(0.13)](/filings/0000320121-26-000037.md) | [(0.03)](/filings/0000320121-25-000051.md) | not reported | [0.03](/filings/0000320121-26-000024.md) | [0.01](/filings/0000320121-26-000037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [100.0](/filings/0000320121-23-000054.md) | [99.3](/filings/0000320121-25-000011.md) | [93.9](/filings/0000320121-24-000020.md) | [80.1](/filings/0000320121-24-000083.md) | [69.8](/filings/0000320121-24-000093.md) | [54.6](/filings/0000320121-26-000010.md) | [57.8](/filings/0000320121-25-000025.md) | [57.0](/filings/0000320121-25-000039.md) | [59.1](/filings/0000320121-25-000051.md) | [53.2](/filings/0000320121-26-000037.md) | [50.2](/filings/0000320121-26-000024.md) | [50.6](/filings/0000320121-26-000037.md) |
| Current assets | $m | [136](/filings/0000320121-23-000054.md) | [140](/filings/0000320121-25-000011.md) | [123](/filings/0000320121-24-000020.md) | [110](/filings/0000320121-24-000083.md) | [99.3](/filings/0000320121-24-000093.md) | [91.4](/filings/0000320121-26-000010.md) | [94.1](/filings/0000320121-25-000025.md) | [103](/filings/0000320121-25-000039.md) | [103](/filings/0000320121-25-000051.md) | [94.4](/filings/0000320121-26-000037.md) | [95.6](/filings/0000320121-26-000024.md) | [96.8](/filings/0000320121-26-000037.md) |
| Total assets | $m | [205](/filings/0000320121-23-000054.md) | [209](/filings/0000320121-25-000011.md) | [195](/filings/0000320121-24-000020.md) | [182](/filings/0000320121-24-000083.md) | [166](/filings/0000320121-24-000093.md) | [158](/filings/0000320121-26-000010.md) | [158](/filings/0000320121-25-000025.md) | [165](/filings/0000320121-25-000039.md) | [164](/filings/0000320121-25-000051.md) | [140](/filings/0000320121-26-000037.md) | [140](/filings/0000320121-26-000024.md) | [140](/filings/0000320121-26-000037.md) |
| Current liabilities | $m | [29.6](/filings/0000320121-23-000054.md) | [39.2](/filings/0000320121-25-000011.md) | [30.4](/filings/0000320121-24-000020.md) | [23.2](/filings/0000320121-24-000083.md) | [27.3](/filings/0000320121-24-000093.md) | [22.1](/filings/0000320121-26-000010.md) | [23.5](/filings/0000320121-25-000025.md) | [38.7](/filings/0000320121-25-000039.md) | [37.3](/filings/0000320121-25-000051.md) | [36.8](/filings/0000320121-26-000037.md) | [37.0](/filings/0000320121-26-000024.md) | [40.6](/filings/0000320121-26-000037.md) |
| Total liabilities | $m | [40.7](/filings/0000320121-23-000054.md) | [49.7](/filings/0000320121-25-000011.md) | [41.0](/filings/0000320121-24-000020.md) | [33.2](/filings/0000320121-24-000083.md) | [36.8](/filings/0000320121-24-000093.md) | [31.1](/filings/0000320121-26-000010.md) | [31.9](/filings/0000320121-25-000025.md) | [46.6](/filings/0000320121-25-000039.md) | [44.6](/filings/0000320121-25-000051.md) | [43.9](/filings/0000320121-26-000037.md) | [43.4](/filings/0000320121-26-000024.md) | [46.3](/filings/0000320121-26-000037.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [164](/filings/0000320121-24-000093.md) | [159](/filings/0000320121-26-000010.md) | [154](/filings/0000320121-25-000039.md) | [149](/filings/0000320121-25-000051.md) | [129](/filings/0000320121-25-000051.md) | [127](/filings/0000320121-26-000037.md) | [126](/filings/0000320121-26-000037.md) | [118](/filings/0000320121-26-000037.md) | [120](/filings/0000320121-25-000051.md) | [96.0](/filings/0000320121-26-000037.md) | [96.5](/filings/0000320121-26-000037.md) | [93.4](/filings/0000320121-26-000037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.8 d](/filings/0000320121-24-000093.md) | [5.0 d](/filings/0000320121-25-000011.md) | [(0.4)](/filings/0000320121-25-000025.md) | [(8.0) d](/filings/0000320121-25-000039.md) | [(7.1) d](/filings/0000320121-25-000051.md) | [(10.5) d](/filings/0000320121-26-000010.md) | [6.1](/filings/0000320121-26-000024.md) | [7.0 d](/filings/0000320121-26-000037.md) | [9.1 d](/filings/0000320121-25-000051.md) | [8.0 d](/filings/0000320121-26-000010.md) | [8.7](/filings/0000320121-26-000024.md) | [8.8 d](/filings/0000320121-26-000037.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000320121-24-000093.md) | [0.6 d](/filings/0000320121-25-000011.md) | [0.1](/filings/0000320121-25-000025.md) | [0.2 d](/filings/0000320121-25-000039.md) | [0.0 d](/filings/0000320121-25-000051.md) | [1.9 d](/filings/0000320121-26-000010.md) | [0.1](/filings/0000320121-26-000024.md) | [0.1 d](/filings/0000320121-26-000037.md) | [0.5 d](/filings/0000320121-25-000051.md) | [0.0 d](/filings/0000320121-26-000010.md) | [0.1](/filings/0000320121-26-000024.md) | [0.2 d](/filings/0000320121-26-000037.md) |
| Share repurchases | $m | [0.0 d](/filings/0000320121-24-000093.md) | [0.0 d](/filings/0000320121-25-000011.md) | [0.0](/filings/0000320121-24-000020.md) | [0.0 d](/filings/0000320121-25-000039.md) | [0.0 d](/filings/0000320121-25-000051.md) | [0.0 d](/filings/0000320121-26-000010.md) | [0.0](/filings/0000320121-26-000024.md) | [4.0 d](/filings/0000320121-26-000037.md) | [3.6 d](/filings/0000320121-25-000051.md) | [6.0 d](/filings/0000320121-26-000010.md) | [2.2](/filings/0000320121-26-000024.md) | [4.7 d](/filings/0000320121-26-000037.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [67.5](/filings/0000320121-23-000054.md) | [68.2](/filings/0000320121-24-000020.md) | [69.4](/filings/0000320121-24-000083.md) | [69.6](/filings/0000320121-24-000093.md) | [70.6](/filings/0000320121-25-000025.md) | [72.0](/filings/0000320121-25-000039.md) | [72.3](/filings/0000320121-25-000051.md) | [72.7](/filings/0000320121-26-000024.md) | [73.2](/filings/0000320121-26-000037.md) | [72.6](/filings/0000320121-25-000051.md) | [77.6](/filings/0000320121-26-000024.md) | [77.5](/filings/0000320121-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 74,736,789 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0000320121-26-000037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.